GKOS GLAUKOS Corp

  1. Stocks
  2. Healthcare
  3. NYSE: GKOS

Price (delayed)

$45.02

Market cap

$2.1B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.31

Enterprise value

$2.34B

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, ...

Highlights
The company's gross profit has surged by 59% YoY and by 31% QoQ
The revenue has grown by 34% YoY and by 20% from the previous quarter
The quick ratio has plunged by 83% YoY
The debt has increased by 44% YoY and by 3.3% QoQ
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.glaukos.com
Peers: ICUI IART ATRC HRC

Key stats

What are the main financial stats of GKOS
Market
Shares outstanding
46.56M
Market cap
$2.1B
Enterprise value
$2.34B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.57
Price to sales (P/S)
7.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.24
Earnings
Revenue
$284.13M
EBIT
-$46.1M
EBITDA
-$11.65M
Free cash flow
-$19.36M
Per share
EPS
-$1.31
Free cash flow per share
-$0.42
Book value per share
$12.63
Revenue per share
$6.14
TBVPS
$13.66
Balance sheet
Total assets
$1.04B
Total liabilities
$459.4M
Debt
$372.38M
Equity
$584.33M
Working capital
$141.06M
Liquidity
Debt to equity
0.64
Current ratio
1.4
Quick ratio
1.33
Net debt/EBITDA
-21.01
Margins
EBITDA margin
-4.1%
Gross margin
74.7%
Net margin
-21.2%
Operating margin
-17.5%
Efficiency
Return on assets
-5.9%
Return on equity
-9.6%
Return on invested capital
-7.6%
Return on capital employed
-6.6%
Return on sales
-16.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GKOS stock price

How has the GLAUKOS stock price performed over time
Intraday
0.24%
1 week
-0.77%
1 month
-11.03%
1 year
-22.71%
YTD
-40.18%
QTD
-6.54%

Financial performance

How have GLAUKOS's revenue and profit performed over time
Revenue
$284.13M
Gross profit
$212.21M
Operating income
-$49.77M
Net income
-$60.35M
Gross margin
74.7%
Net margin
-21.2%
The company's operating margin has surged by 74% YoY and by 50% QoQ
GKOS's operating income has soared by 65% YoY and by 40% QoQ
The company's gross profit has surged by 59% YoY and by 31% QoQ
The net margin has increased by 39% QoQ and by 37% YoY

Growth

What is GLAUKOS's growth rate over time

Valuation

What is GLAUKOS stock price valuation
P/E
N/A
P/B
3.57
P/S
7.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.24
GLAUKOS's EPS has increased by 28% from the previous quarter and by 14% YoY
The price to book (P/B) is 59% less than the 5-year quarterly average of 8.7 and 34% less than the last 4 quarters average of 5.4
GLAUKOS's equity has decreased by 12% YoY
The P/S is 47% lower than the last 4 quarters average of 13.8 and 31% lower than the 5-year quarterly average of 10.6
The revenue has grown by 34% YoY and by 20% from the previous quarter

Efficiency

How efficient is GLAUKOS business performance
The ROIC has soared by 81% year-on-year and by 41% since the previous quarter
GLAUKOS's ROS has soared by 76% YoY and by 50% from the previous quarter
The return on assets is up by 40% year-on-year and by 28% since the previous quarter
The ROE has grown by 27% YoY and by 25% from the previous quarter

Dividends

What is GKOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GKOS.

Financial health

How did GLAUKOS financials performed over time
The total assets is 127% greater than the total liabilities
GKOS's current ratio has dropped by 83% year-on-year
The quick ratio has plunged by 83% YoY
The debt is 36% lower than the equity
The debt to equity has soared by 64% YoY and by 4.9% from the previous quarter
The debt has increased by 44% YoY and by 3.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.